Pharma Equity Group Past Earnings Performance
Past criteria checks 0/6
Pharma Equity Group's earnings have been declining at an average annual rate of -160.6%, while the Real Estate industry saw earnings growing at 3.8% annually.
Key information
-160.6%
Earnings growth rate
-130.1%
EPS growth rate
Real Estate Industry Growth | 27.6% |
Revenue growth rate | n/a |
Return on equity | -63.2% |
Net Margin | n/a |
Next Earnings Update | 16 May 2024 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Pharma Equity Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -25 | 16 | 9 |
30 Sep 23 | 0 | -14 | 9 | 8 |
30 Jun 23 | 0 | -12 | 7 | 7 |
31 Mar 23 | 0 | -10 | 7 | 5 |
Quality Earnings: PEG is currently unprofitable.
Growing Profit Margin: PEG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if PEG's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare PEG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEG is unprofitable, making it difficult to compare its past year earnings growth to the Real Estate industry (-24.7%).
Return on Equity
High ROE: PEG has a negative Return on Equity (-63.21%), as it is currently unprofitable.